Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Mycobacterium vaccae for injection in the preparation of medicines for preventing and treating covid-19

A COVID-19, Mycobacterium vaccae technology, applied in the field of medicine, can solve the problems of inaccurate actual therapeutic effect and large adverse reactions of exogenous IFN

Active Publication Date: 2021-11-19
THE FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, in the latest diagnosis and treatment plan ("Diagnosis and Treatment Plan for Pneumonia Infected by Novel Coronavirus (Trial Version 5 and 6)" issued by the National Health and Health Commission on January 27, 2020), nebulized inhalation of α-IFN (500 mg per adult for adults) is recommended. 10,000 U, add 2ml of sterile water for injection, twice a day), but its actual therapeutic effect is still uncertain. Consider its high cost and whether aerosol inhalation of α-IFN can reach the lower respiratory tract and lung tissue

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Mycobacterium vaccae for injection in the preparation of medicines for preventing and treating covid-19
  • Application of Mycobacterium vaccae for injection in the preparation of medicines for preventing and treating covid-19
  • Application of Mycobacterium vaccae for injection in the preparation of medicines for preventing and treating covid-19

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1 (ordinary patient):

[0029] The use of Mycobacterium vaccae for injection in the preparation of medicines for the prevention and treatment of COVID-19.

[0030] Mycobacterium vaccae (microcalorie) for injection 22.5 micrograms / bottle × 2 + physiological saline 10ml was made into physiological saline injection, using SW-Ⅱ type jet nebulizer, jet flow under the oxygen flow of 5L / min Atomize and inhale until all the liquid medicine is inhaled (about 20 minutes), Qd, 10 days / course of treatment; spray and inhale salbutamol sulfate aerosol before atomization, namely "Ventolin" 3 sprays.

Embodiment 2

[0031] Example 2 (critically ill patient):

[0032] Mix Mycobacterium vaccae (microcalorie) for injection 25 micrograms / bottle x 2 bottles + salbutamol in a weight ratio of 1:50-200 into a sterile mixture of 10ml of normal saline, using a SW-II jet nebulizer, Under the oxygen flow rate of 5L / min, jet atomization inhalation, until all the liquid medicine is inhaled (about 20 minutes), Qd, 10 days / course of treatment.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicine, and in particular relates to the application of Mycobacterium vaccae for injection in the preparation of medicines for preventing and treating COVID‑19 (diseases caused by novel coronaviruses). The Mycobacterium vaccae for injection can rapidly increase the level of endogenous interferon in respiratory tract-lung tissue to inhibit viral RNA replication, reduce cell damage or promote repair of damaged cells to prevent and treat, while avoiding or reducing The unavoidable adverse reactions of exogenous interferon preparations were avoided. The medicine made by the present invention can be inhaled by nebulization, and the medicine provided to the patient can improve the compliance of the patient, make the medicine convenient for the patient, relieve the patient from turning into a severe or critical illness, and shorten the mean time of nucleic acid turning negative. About 4 days, the treatment time is also shortened accordingly, reducing medical expenses. The new application of the Mycobacterium vaccae for injection disclosed in the invention in the preparation of drugs for preventing and treating COVID-19 provides a new solution for clinical prevention and treatment of COVID-19 and respiratory virus infection.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the application of Mycobacterium vaccae for injection in the preparation of a medicine for preventing and treating COVID-19 (disease caused by novel coronavirus). Background technique [0002] The country is facing a major outbreak of severe COVID-19 (the disease caused by the novel coronavirus). Although the country quickly isolated and identified it as a new type of coronavirus, due to insufficient understanding or controversy about the source of infection, transmission route, susceptible hosts, disease characteristics and regularity of the new type of coronavirus, and lack of effective treatment methods, and The large migration of people during the Spring Festival has led to a sharp rise in the number of infected patients, and the current epidemic prevention and control is still very severe. As of 2020-2-2424:00 National statistics, a total of 77,658 new coronavi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K35/74A61P11/00A61P31/14A61P31/12
CPCA61K35/74A61P11/00A61P31/12A61P31/14
Inventor 李超乾林艳荣
Owner THE FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products